Name: Giant Knotweed Extract
Active Ingredients: Trans-Resveratrol
CAS NO.: 501-36-0
Molecular Formula: C14-H12-O3
Molecular Weight: 228.246
Structure:

Specification: Trans-Resveratrol NLT 8%, 20%, 50%
Test method: HPLC
Botanical Source: Polygonum cuspidatum
Used part:Root
Packing: 25KG/package
Storage: Store in cool and dry place and keep away from strong direct light and heat
Shelf Life: Two years when properly stored
Applications :
What is Giant Knotweed Extract?
The active ingredient of Giant Knotweed Extract is Resveratrol. Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a stilbenoid, a type of natural phenol, and a phytoalexin  produced naturally by several plants in response to injury or when the plant is under attack by pathogens such as bacteria or fungi. Food sources of resveratrol include the skin of grapes, blueberries, raspberries, and mulberries.

Health Benefits of Giant Knotweed Extract
There are promising animal studies and some data from human clinical trials is emerging. Nowadays, Resveratrol is widely used in dietary supplements, functional beverage. The main functions of Resveratrol are as follows:

Anti-Cancer
As of 2014, the results of human clinical trials with small samples sizes of the effects of resveratrol on cancer are shown. Testing of resveratrol in animal models of cancer have also shown mixed results. The strongest evidence of anticancer action of resveratrol exists for tumors it can contact directly, such as skin and gastrointestinal tract tumors. For other cancers, the evidence is certain.

Cardio protective effects
Moderate drinking of red wine is associated with a reduced risk of heart disease. This is best known as "the French paradox".
Studies suggest resveratrol in red wine may play an important role in this phenomenon. It appears to stimulate endothelial nitric oxide synthase (eNOS) activity and inhibit platelet aggregation.

Antidiabetic effects

Animal studies have demonstrated an antidiabetic effects of resveratrol. This compound was shown to act as agonist of PPAR gamma, nuclear receptor that is current pharmacological target for the treatment of diabetes type 2.